Syngene International Limited today announced results for the first quarter of FY26. Revenue for the quarter increased by 10.7% from last year to Rs.874.5 crore. 

Net profit for the period increased by 14.5% from last year to Rs. 83.7 crore. The profit figure for the quarter includes tax benefits from transfer of gratuity funds to Employee Gratuity Trust. Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) stood at Rs. 206.4 crore from Rs. 169.8 crore. 

Commenting on the results, Peter Bains, Managing Director and CEO, Syngene International Limited, said, “We are pleased with the growth performance in the first quarter, which is aligned with our expectations. Continued conversion of pilot programs into longer-term contracts within our Research Services business was the main driver underpinning this momentum. In our Biologics manufacturing division, we have seen good progress with the start of operations at the Unit III facility in Bengaluru and in advancing preparations to commence operations at our Bayview facility in the U.S later this year. We continued to strengthen and expand our scientific platform capabilities, bringing online a state-of-the-art, dedicated peptide laboratory. While we remain mindful of ongoing macroeconomic factors, we maintain a confident outlook.” 

Deepak Jain, Chief Financial Officer, Syngene International Limited, said, “We are pleased with the growth in revenue from operations of 11% year-on-year. Operating EBITDA margins came at around 24%, driven by both revenue growth and a focus on cost optimization. The current quarter’s PAT includes a tax benefit arising from transfer of gratuity funds to Employee Gratuity Trust. We continue to maintain a robust balance sheet enabling us to invest in technology and capabilities to strengthen our customer offerings. While keeping a close watch on market trends, we remain on course to deliver in line with our stated guidance for the year.”